Intellia Therapeutics (NASDAQ:NTLA) Shares Down 8.3% - What's Next?

Key Points

• Intellia shares fell 8.3% to $11.11 in Tuesday trading, while volume was 78% below its average.
• The company missed quarterly expectations, reporting a loss of $0.91 per share versus an expected $0.80 loss and revenue of $7.16 million versus $9.74 million expected; revenue declined 47.8% year over year.
• Analyst views are mixed: HC Wainwright maintained a Buy rating and $25 target while cutting earnings forecasts. MarketBeat reports an average rating of Hold and an average price target of $21.44.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) fell 8.3% on Tuesday. The stock traded as low as $11.08 and last traded at $11.11. Approximately 1,127,780 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 5,103,586 shares. The stock had previously closed at $12.11.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, signaling continued confidence despite lowering its earnings forecasts.
• Neutral Sentiment: Intellia reported inducement grants under Nasdaq listing rules; the provided report does not specify their size or likely financial impact. Intellia Therapeutics reports inducement grants
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS estimates, including its FY2026 forecast to a loss of $3.24 per share from $3.06 and its FY2027 forecast to a loss of $3.17 from $3.12. It also reduced estimates for several 2027 quarters.
• Negative Sentiment: Brookline Capital Markets cut its FY2026 estimate to a loss of $2.92 per share and lowered its longer-term profit forecasts for 2029 and 2030, tempering expectations for future earnings growth.
• Negative Sentiment: The company’s latest reported quarter also missed analyst expectations for both EPS and revenue; revenue fell 47.8% year over year. These results add to the concerns reflected in the forecast cuts.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of recent analyst reports. Wedbush upped their target price on Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Wednesday, September 9th. Evercore upgraded Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price target on the stock in a research report on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Barclays initiated coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They issued an "underweight" rating and a $8.00 price objective for the company. Finally, Wall Street Zen lowered Intellia Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Hold" and an average target price of $21.44.

Intellia Therapeutics Stock Down 7.5%

The company's fifty day moving average price is $12.08 and its 200-day moving average price is $13.04. The stock has a market capitalization of $1.57 billion, a PE ratio of -3.34 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The company had revenue of $7.16 million during the quarter, compared to analysts' expectations of $9.74 million. During the same quarter in the previous year, the company earned ($0.92) EPS. The business's quarterly revenue was down 47.8% on a year-over-year basis. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 9,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares of the company's stock, valued at approximately $13,645,387.36. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. Bank of America Corp DE raised its position in Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company's stock worth $17,713,000 after buying an additional 139,325 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Intellia Therapeutics by 1,082.1% during the 1st quarter. Royal Bank of Canada now owns 465,499 shares of the company's stock valued at $5,968,000 after acquiring an additional 426,121 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at about $1,595,000. Assenagon Asset Management S.A. purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $3,875,000. Finally, BlackRock Inc. bought a new stake in shares of Intellia Therapeutics in the second quarter worth approximately $260,721,000. Institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient's body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia's investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.